Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tolperisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.97 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.72 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.72 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.72 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.72 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.62 |
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | MITF | O75030 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolperisone SCHEMBL148499 | 0.98 | CHRM2 (1.00) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Tolperisone SCHEMBL4780118 | 0.98 | CHRM2 (1.00) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Tolperisone SCHEMBL17223884 | 0.98 | CHRM2 (1.00) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Tolperisone SCHEMBL4516510 | 0.98 | CHRM2 (1.00) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| SCHEMBL21451092 | 0.98 | CHRM2 (1.00) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| SCHEMBL9172663 | 0.97 | CHRM2 (0.97) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Tolperisone SCHEMBL15663055 | 0.95 | CHRM2 (0.94) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Deutolperisone SCHEMBL5371621 | 0.88 | CHRM2 (0.81) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Tolperisone SCHEMBL5356342 | 0.88 | CHRM2 (0.81) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Hydrochloric Acid SCHEMBL10846353 | 0.88 | ALDH1A1 (0.78) | ALDH1A1LMNACHRM2ADRA2BDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120121747-A | Method for simultaneously measuring tolperisone hydrochloride, methyl hesperidin and vitamin B6 content in Naoluotong capsule | 浙江省食品药品检验研究院(《中国现代应用药学》杂志社) | 2025-06-10 | — | — | CN | claimed |
| US-12292363-B2 | Method for preparing biological material having excellent light-transmitting property | RIKEN (JP) | 2025-05-06 | — | — | US | claimed |
| CN-119488493-A | Naoluotong capsule and preparation method thereof | 一力制药(罗定)有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-116785177-A | Formula and process of Naoluotong capsule | 盘锦市兴隆台区创新创业合作社 | 2023-09-22 | — | — | CN | claimed |
| CN-110845443-B | Method for preparing high-purity tolperisone hydrochloride | 嘉实（湖南）医药科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116253699-A | New crystal form of tolperisone hydrochloride and preparation method thereof | 广州白云山汉方现代药业有限公司 | 2023-06-13 | — | — | CN | claimed |
| CN-116173100-A | Formula of Naoluotong capsule and production equipment thereof | 辽宁天龙药业有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-116174108-A | Formula of Naoluotong capsule and production equipment thereof | 辽宁天龙药业有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-115932082-A | Method for determining tolperisone hydrochloride related substances | 嘉实（湖南）医药科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-113197947-B | Composition for clearing and activating channels and collaterals and dredging blood vessels and preparation method thereof | 一力制药（罗定）有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| US-6500455-B1 | Tolperison-containing, pharmaceutical preparation for oral administration | SANOCHEMIA PHARMAZEUTIKA (AT) | 2002-12-31 | — | — | US | claimed |
| US-6451850-B1 | Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum | Soloviev, Evgeny Vladimirovich (FR) | 2002-09-17 | — | — | US | claimed |
| EP-1105117-A1 | BIO-CHEMICAL GERMANIUM COMPLEXES WITH HIGH THERAPEUTIC EFFICIENCY AND WIDE APPLICATION SPECTRUM | Soloviev, Evgeny Vladimirovich (FR) | 2001-06-13 | — | — | EP | claimed |
| WO-2000010561-A1 | BIO-CHEMICAL GERMANIUM COMPLEXES WITH HIGH THERAPEUTIC EFFICIENCY AND WIDE APPLICATION SPECTRUM | SOLOVIEV EVGENY VLADIMIROVICH (FR) | 2000-03-02 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5252588-A | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-10-12 | — | — | US | claimed |
| US-5073375-A | Monoglyceride or lactic acid ester | SANSHO CO., LTD. (JP) | 1991-12-17 | — | — | US | claimed |
| US-5059427-A | PHARMACEUTICAL PREPARATION FOR PERCUTANEOUS ADMINISTRATION CONTAINING EPERISONE OR TOLPERISONE OR SALT THEREOF | SANSHO CO., LTD. (JP) | 1991-10-22 | — | — | US | claimed |